STOCK TITAN

Viridian Therapeutics, Inc. - VRDN STOCK NEWS

Welcome to our dedicated page for Viridian Therapeutics news (Ticker: VRDN), a resource for investors and traders seeking the latest updates and insights on Viridian Therapeutics stock.

Viridian Therapeutics, Inc. (NASDAQ: VRDN) is a clinical-stage biopharmaceutical company focused on developing innovative therapies for patients suffering from thyroid eye disease (TED). The company's primary product candidate, VRDN-001, is an insulin-like growth factor-1 receptor (IGF-1R) monoclonal antibody (mAb) that holds promise for treating TED, a rare and debilitating condition.

Viridian Therapeutics leverages cutting-edge science and a deep understanding of disease biology to advance its therapeutic candidates. Their lead candidate, VRDN-001, is aimed at mitigating the symptoms of TED, which include inflammation, pain, and vision impairment. By targeting IGF-1R, VRDN-001 has the potential to offer a novel treatment option for patients who currently have limited choices.

The company’s commitment to scientific excellence is reflected in its rigorous clinical trials and strategic partnerships. Viridian collaborates with leading academic institutions and industry partners to enhance the development and potential commercialization of its therapies. These collaborations provide valuable resources and expertise, helping to accelerate the progress of their drug candidates.

In terms of financial health, Viridian Therapeutics is well-positioned with sufficient funding to advance its clinical programs. The company continuously explores opportunities to bolster its financial stability through strategic partnerships and potential equity financing. Viridian's prudent financial management ensures that it can sustain its operations and continue its mission to bring transformative therapies to patients in need.

Viridian's focus on thyroid eye disease addresses a significant unmet medical need. The company aims to develop treatments that improve the quality of life for patients suffering from this challenging condition. By pursuing innovative approaches and maintaining a patient-centric mindset, Viridian is making meaningful strides in the field of biopharmaceuticals.

Stay updated with the latest news and developments from Viridian Therapeutics as they progress in their mission to deliver groundbreaking therapies for underserved patient populations.

Rhea-AI Summary

Viridian Therapeutics, Inc. (NASDAQ: VRDN) will host a webcast to discuss its first quarter 2024 financial results and recent business highlights on May 8, 2024. The company focuses on discovering medicines for serious and rare diseases.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.59%
Tags
conferences earnings
-
Rhea-AI Summary
Viridian Therapeutics, Inc. announced the approval of non-qualified stock options for new employees. The Inducement Grants consist of 102,000 shares of common stock, granted outside the company's Equity Incentive Plan. The options have an exercise price equal to the closing price on the Grant Date and will vest over a four-year period.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary
Viridian Therapeutics (VRDN) announces the approval of non-qualified stock options for new employees, totaling 62,000 shares, granted as an inducement for joining the company. The options will vest over a four-year period, aligning with Nasdaq Listing Rule 5635(c)(4).
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.25%
Tags
none
Rhea-AI Summary
Viridian Therapeutics, Inc. (NASDAQ: VRDN) will participate in a fireside chat at the Leerink Partners Global Biopharma Conference on March 11. The event will focus on discovering and developing medicines for serious and rare diseases.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.93%
Tags
conferences
-
Rhea-AI Summary
Viridian Therapeutics, Inc. (NASDAQ: VRDN) reported recent business highlights and financial results for Q4 and full year 2023. They anticipate Phase 3 clinical data readouts for VRDN-001 in mid-year 2024 and VRDN-003 pivotal program in thyroid eye disease to start mid-year 2024. The company raised $150 million in gross proceeds from a public offering in January 2024, extending their operating runway into the second half of 2026.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.86%
Tags
-
Rhea-AI Summary
Viridian Therapeutics appoints Jennifer Tousignant as Chief Legal Officer and grants her 290,000 stock options. Ms. Tousignant brings extensive experience from Sana Biotechnology, Xilio Therapeutics, and TESARO, Inc. The company aims to develop best-in-class medicines for thyroid eye disease and anti-neonatal Fc receptor portfolios.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.33%
Tags
management
Rhea-AI Summary
Viridian Therapeutics, Inc. announced the approval of a non-qualified stock options grant to an employee to purchase up to 30,000 shares of the company's common stock. The grant was made as an inducement for the individual entering into employment with Viridian and will vest over a four-year period.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.06%
Tags
none
-
Rhea-AI Summary
Viridian Therapeutics, Inc. (NASDAQ: VRDN) has announced the pricing of an underwritten public offering with gross proceeds of approximately $150.0 million. The company is selling a total of 7,142,858 shares of common stock at a public offering price of $21.00 per share. Additionally, they have granted the underwriters a 30-day option to purchase an additional 1,071,428 shares of common stock. The offering is expected to close soon.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.73%
Tags
-
Rhea-AI Summary
Viridian Therapeutics, Inc. (NASDAQ: VRDN) has announced an underwritten public offering of shares of its common stock and Series B preferred stock. The company intends to use the proceeds for clinical development programs, working capital, and general corporate purposes. Jefferies and Leerink Partners are acting as joint lead book-running managers for the proposed offering.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.73%
Tags
Rhea-AI Summary
Viridian Therapeutics, a biotechnology company (NASDAQ: VRDN), announced plans for clinical trials for thyroid eye disease treatments and progress on FcRn portfolio at the 42nd Annual J.P. Morgan Healthcare Conference. Key updates include VRDN-001 Phase 3 trials for active and chronic TED, VRDN-003 pivotal study, and VRDN-006 IND anticipated by year-end 2024. Dr. Thomas Ciulla promoted to Chief Medical Officer.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.78%
Tags
conferences

FAQ

What is the current stock price of Viridian Therapeutics (VRDN)?

The current stock price of Viridian Therapeutics (VRDN) is $19.31 as of December 24, 2024.

What is the market cap of Viridian Therapeutics (VRDN)?

The market cap of Viridian Therapeutics (VRDN) is approximately 1.5B.

What does Viridian Therapeutics, Inc. do?

Viridian Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing therapies for thyroid eye disease, with a primary focus on their product candidate VRDN-001.

What is VRDN-001?

VRDN-001 is an insulin-like growth factor-1 receptor (IGF-1R) monoclonal antibody being developed by Viridian Therapeutics for the treatment of thyroid eye disease.

What condition does Viridian Therapeutics aim to treat?

Viridian Therapeutics is focused on developing treatments for thyroid eye disease, a rare and debilitating condition.

How does VRDN-001 work?

VRDN-001 targets the insulin-like growth factor-1 receptor (IGF-1R) to potentially reduce inflammation, pain, and vision impairment associated with thyroid eye disease.

Who are Viridian Therapeutics' partners?

Viridian collaborates with leading academic institutions and industry partners to enhance the development and potential commercialization of its therapies.

What is the financial condition of Viridian Therapeutics?

Viridian Therapeutics is well-positioned with sufficient funding to advance its clinical programs and explores opportunities for strategic partnerships and equity financing.

Why is thyroid eye disease a focus for Viridian Therapeutics?

Thyroid eye disease represents a significant unmet medical need with limited treatment options, and Viridian aims to develop therapies that improve the quality of life for these patients.

How can I stay updated on Viridian Therapeutics' progress?

You can stay updated by following the latest news and developments from Viridian Therapeutics as they advance their clinical programs and partnerships.

Where is Viridian Therapeutics listed?

Viridian Therapeutics is listed on the NASDAQ stock exchange under the ticker symbol VRDN.

What makes Viridian Therapeutics' approach unique?

Viridian Therapeutics leverages in-depth disease biology knowledge and cutting-edge science to develop innovative therapies, particularly targeting the IGF-1R pathway for thyroid eye disease.

Viridian Therapeutics, Inc.

Nasdaq:VRDN

VRDN Rankings

VRDN Stock Data

1.53B
76.37M
0.01%
112.12%
11.48%
Biotechnology
Services-medical Laboratories
Link
United States of America
WALTHAM